Trial Profile
An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics, and Efficacy of BI 754091 in Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Ezabenlimab (Primary)
- Indications Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Gastric cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 18 Sep 2023 Status changed from active, no longer recruiting to completed.
- 31 May 2023 Planned End Date changed from 1 Aug 2023 to 6 Sep 2023.
- 06 Feb 2023 Planned End Date changed from 30 Jun 2023 to 1 Aug 2023.